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Abstract: Mycobacterium africanum consists of two
phylogenetically distinct lineages within the Mycobacteri-
um tuberculosis complex, known as M. africanum West
African 1 and M. africanum West African 2. These lineages
are restricted to West Africa, where they cause up to half
of human pulmonary tuberculosis. In this review we
discuss the definition of M. africanum, describe the
prevalence and restricted geographical distribution of M.
africanum West African 1 and 2, review the occurrence of
M. africanum in animals, and summarize the phenotypic
differences described thus far between M. africanum and
M. tuberculosis sensu stricto.
Introduction
Mycobacterium africanum causes up to half of human tuberculosis
(TB) in West Africa [1,2]. It was first described as a distinct sub-
species within the Mycobacterium tuberculosis complex (MTBC) by
Castets and colleagues in 1968 [3]. M. africanum yields variable
results on classical biochemical characterization, which has
complicated the proper classification of the sub-species. This
classification has been revised since the advent of molecular
genotyping techniques (Figure 1) [4]. Thus, M. africanum type I
(West African clade) has recently been sub-divided into M.
africanum type I, West African 1 (MAF1), prevalent around the
Gulf of Guinea, and M. africanum type I, West African 2 (MAF2),
prevalent in western West Africa [5] (Figure 1). The M. africanum
type II (East African clade) has been reclassified into M. tuberculosis
sensu stricto (Figure 1) [4], and is indicated as ‘‘Uganda’’ genotype
in Figure 2. Castets wrote a French review on M. africanum in 1979
[6]. While both M. africanum type I and type II were previously
reviewed by Onipede and colleagues [7], this review focuses on the
two West African lineages within M. africanum type I, MAF1 and
MAF2. We use the term ‘‘M. africanum’’ when referencing studies
in which no molecular distinction between MAF1 and MAF2 was
included or when MAF1 and MAF2 were described together.
Methods
We searched PubMed, Web of Knowledge, and Embase
databases using the terms ‘‘Mycobacterium africanum’’ and ‘‘M.
africanum’’, and identified further references in these articles.
Results
Definition of M. africanum
In 1968 in Dakar, Senegal, Castets and colleagues reported
mycobacterial strains that, in biochemical testing, were interme-
diaries between M. tuberculosis and Mycobacterium bovis, and named
these mycobacteria Mycobacterium africanum [3]. Like M. tuberculosis,
M. africanum strains were found to be sensitive to pyrazinamide.
However, like M. bovis, M. africanum tended to be nitrate negative, a
weak producer of niacin, and to grow microaerophilically in media
supplemented with pyruvate, albeit with variable results (Table 1,
[8]). Meissner described similar isolates from Ghana in 1969 [9].
On Lowenstein-Jensen solid agar, M. africanum grew more slowly
than M. tuberculosis, with cultures occasionally yielding growth only
after 10 weeks, compared to 3–4 weeks in M. tuberculosis [10,11].
Castets thus recommended a 90-day incubation for isolation of M.
africanum [6]. In minimal media using glucose as sole carbon
source, M. africanum could not use L-alanine as sole nitrogen
source, similar to M. bovis [12]. Using colony morphology and
biochemical results, a distinction was made between the Dakar
variety of M. africanum, which likely corresponds to MAF2, and a
Yaounde variety, which likely corresponds to MAF1, as well as a
Rwanda variety that may have corresponded with the former East
African M. africanum type II (i.e., today’s Uganda genotype of M.
tuberculosis) [13,14]. However, studies based on molecular typing
have shown that M. africanum isolates can exhibit a whole range of
biochemical phenotypes [4], which complicates unambiguous
classification based on phenotypic testing. By contrast, molecular-
based taxonomy is more reliable if appropriate molecular markers
are used. Based on the traditional genotyping tools used for
routine molecular epidemiological investigation (i.e., IS6110
RFLP and spoligotype analysis), M. africanum exhibits a few
characteristics that, however, are not always diagnostic [15]. For
example, spoligotype patterns tend to permit unambiguous
classification, lacking spacers 8 through 12 and 37 through 39 in
MAF1 and spacers 7 through 9 and 39 in MAF2 [2,16].
However, for strains that lack the MAF1- or MAF2-specific
spacers as well as spacers 33–36, additional molecular tests are
required for classification, as such spoligotype patterns could also
indicate Euro-American M. tuberculosis. Members of MAF1
typically show more than five IS6110 copies and MAF2 generally
harbors five or fewer IS6110 copies [17,18]. The completion of the
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a mycobacterial classification system based on genomic deletions
or large sequence polymorphisms (LSPs) [19]. Because the MTBC
has a clonal population structure with essentially no horizontal
gene exchange, genomic deletions are irreversible and hence
represent robust phylogenetic markers. The presence or absence of
particular genomic regions of difference can be used to define
specific lineages within the MTBC [20]. Following such an
approach, initial studies established that MAF1 and MAF2 are
distinct lineages, with MAF1 sharing the RD9 deletion with MAF2
and M. bovis, while MAF2 and M. bovis share additional deletions
of RD7, RD8, and RD10 (Figure 2) [21,22]. These studies also
demonstrated that M. africanum type II is in fact a member of M.
tuberculosis sensu stricto as it contains the TbD1 deletion, which is a
characteristic marker for a subset of M. tuberculosis (Figure 2) [21].
Subsequent studies in which M. africanum DNA was compared to
M. tuberculosis H37Rv using comparative genome hybridization
identified additional LSPs that are specific to MAF1 (RD711) and
to MAF2 (RD702; Table 1) [4,5].
Recently, a large-scale multilocus sequence analysis identified
multiple single nucleotide polymorphisms (SNPs) specific to
MAF1, MAF2, and former M. africanum type II (Figure 2, Table
S1) [23]. These SNPs can thus be used to define these M. africanum
lineages unambiguously [15]. The study by Hershberg and
colleagues [23] also highlights the large genetic distance that
separates MAF1 and MAF2 when compared with other lineages
within the MTBC (Figure 2). This high genetic diversity might
lead to important phenotypic differences among and between
MAF1 and MAF2.
Several other genotyping screens for differentiation of the
various species of the MTBC have been developed, such as a PCR
protocol in which MAF1 and MAF2 can be distinguished based on
LSPs and SNPs [24]. A recent publication identified further
polymorphisms specific for MAF1 and for MAF2, as well as two
SNPs in rpoB that define sub-lineages within MAF2 [25].
However, the current commercial speciation tests do not
distinguish between MAF1 and MAF2 (e.g., GenoType MTBC,
Hain Lifescience, Germany).
Prevalence and Distribution of M. africanum
Paleopathological investigation using spoligotype analysis of
human remains from Egypt’s Middle Kingdom (c. 2000–1600
B.C.) identified MAF2 alongside M. tuberculosis [26,27], although
M. africanum has not been identified in North or East Africa since
[28] and has never been identified in Southern Africa [29]. Studies
in Senegal conducted in the 1970s showed that the prevalence of
M. africanum in that country varied by region and averaged 21%
among smear-positive pulmonary TB patients [30] (Table 2).
Studies in other West African countries, using biochemical
speciation, suggested a prevalence of M. africanum ranging from
31% in Mali and Burkina Faso to 66% in Benin [13]. Based on
molecular genotyping results, the prevalence of MAF1 appears
highest in Benin (39%) and Ghana (21%), with a distribution as
shown in Figure 3. Interestingly, the prevalence of MAF1 may be
declining in Cameroon; whereas 30 years ago 56% of TB was
caused by M. africanum based on biochemical speciation [31], an
M. africanum prevalence of only 9% was reported in a recent study
using molecular methods [32]. The prevalence of MAF2 appears
highest in Guinea Bissau, where 51% of smear-positive TB was
caused by MAF2, based on spoligotyping patterns [1]. As shown in
Figure 3, the distributions of MAF1 and MAF2 overlap in
southern West Africa, particularly in Ghana [33] and Benin [34].
M. africanum has sporadically been identified in areas outside of
the West African region, including Germany [9,35,36], England
[37], California [38], France [39], and Spain [40], both from
pulmonary and extra-pulmonary sources. Case reports describe
extra-pulmonary TB caused by M. africanum as disseminated
disease [41], cutaneous disease [42], orchiepididymitis [40],
prostatitis [43], pleural disease [44], bone disease [45], brain
mass [46], and proctitis [47]. However, in most cases, TB patients
carrying M. africanum were immigrants from West Africa. The only
confirmed outbreak of M. africanum outside of West Africa
Figure 1. Nomenclature of M. africanum as related to its biochemical and molecular classification. Biochemical classification is reviewed
in Table 1. LSPs, large sequence polymorphisms [5]. Spoligotype signatures are reviewed in [16].
doi:10.1371/journal.pntd.0000744.g001
www.plosntds.org 2 September 2010 | Volume 4 | Issue 9 | e744Figure 2. The position of M. africanum in the global phylogeny of the M. tuberculosis complex (MTBC) as originally published by
Hershberg et al. [23]. This phylogeny is based on over 65 kb of DNA sequence data (89 concatenated gene sequences) in each of 108 strains of the
MTBC and was inferred using maximum parsimony, which resulted in a single tree with negligable homoplasy [23]. Analysis by the neighbor-joining
method resulted in an identical tree topology with high statistical support for all main branches [23]. This phylogeny has been referred to as the most
robust and most detailed phylogeny of the MTBC to date, and thus should be considered as the new gold standard for classification of the MTBC [87].
The six main MTBC lineages adapted to humans and the animal strains are indicated in different colors. The human MTBC lineages include four M.
tuberculosis lineages and the two M. africanum type I lineages. The ‘‘Uganda’’ genotype (formally referred to as M. africanum type II), which is a sub-
lineage within M. tuberculosis lineage 4 (also known as the Euro-American lineage), is also shown. These lineages are completely congruent to
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drug-resistant (MDR) TB, diagnosed during the period 1989 to
1992, were initially identified as M. bovis on the basis of phenotypic
tests. However, later genotypic analysis identified spoligotype
patterns consistent with MAF1. The index case in this outbreak
originated from Brazil [18], although no MAF1 or MAF2 isolates
have been identified in Brazil [48].
Other studies comparing drug resistance have yielded variable
results: In Ghana, no difference in drug resistance was identified
between M. africanum and M. tuberculosis [49], whereas a previous
regional survey identified more primary resistance among M.
africanum isolates [13]. The Yaounde variant of M. africanum
(corresponding to MAF1) may have higher rates of primary
resistance to thiacetazone [50–52]. This former first-line anti-
tuberculous drug has largely been replaced by rifampicin, because
of a higher incidence of side effects, particularly in patients with
HIV [53]. A recent abstract reported lower drug resistance among
MAF2 isolates from Mali relative to M. tuberculosis [54].
Animal Connection of M. africanum
The proximity of MAF2 to the animal isolates on the
phylogenetic tree of the MTBC (Figure 2) raises the possibility
of an animal reservoir for MAF2. Extensive studies in Senegal in
the 1970s screened cows, sheep, and pigs, as well as soil samples,
but did not identify any non-human reservoir for M. africanum
infection [30]. Neither M. bovis nor other mycobacteria were
detected in these animals. Similarly, a recent extensive search for
bovine TB in The Gambia, Senegal, Guinea Bissau, and Guinea
neither identified tuberculin skin test–positive cows, nor abattoir
samples suggestive of TB [55]. An abattoir survey among sheep
and goats in The Gambia did not yield any evidence for
mycobacterial disease either [56].
M. africanum has sporadically been isolated from animals; it has
been cultured from monkeys from Central and West Africa with
active TB [57], from monkeys in a French veterinary laboratory
[58], from four cows from the same dairy farm in Bangladesh that
were thought to be infected by a caretaker (MAF2, all with a
shared spoligotype pattern, [59]), and twice from a cow in Nigeria
(MAF1 [60], M. africanum [61]). M. africanum can become widely
distributed within the tissues of infected animals, and meat or milk
may be a route of exposure to M. africanum for humans [62].
Efficient human-to-human transmission of MAF2 by aerosol is,
however, suggested by the fact that human contacts sleeping in the
same bedroom as MAF2 patients have higher rates of tuberculin
skin test positivity than contacts sleeping in a different bedroom,
with a similar gradient to the one seen with exposure to M.
tuberculosis [63]. Close interaction between humans and monkeys is
limited in West Africa, and it is unclear whether monkeys form a
reservoir for M. africanum infection, or whether they were
themselves infected by humans or a third animal species.
Experimental Work on M. africanum
A study in cows found that M. africanum, unlike M. tuberculosis,
was equally pathogenic as M. bovis [62]. Other animal studies have
yielded mixed results, possibly due to differences between the two
lineages of M. africanum. When infecting guinea pigs with M.
africanum isolates from Dakar (likely MAF2), virulence, as
measured by the relative weight of the spleen, was lower for M.
africanum than for the laboratory strain M. tuberculosis H37Rv. The
histopathologic lesions observed in the liver resembled those seen
previous classifications based on LSPs [15,23,78]. Black arrows indicate genomic regions or regions of difference (RDs) that are deleted in all
descendent strains belonging to a particular lineage or sub-lineage. The scale indicates the genetic distance as number of SNPs (adapted from
Figure 1 in [23] with additional data from [5]).
doi:10.1371/journal.pntd.0000744.g002
Table 1. Classification of M. africanum Relative to M. tuberculosis and M. bovis.
Characteristic M. africanum Type I M. tuberculosis M. bovis Reference
West African 1 West African 2
Morphological [3]
Colony appearance Dysgonic Dysgonic Eugonic Dysgonic
Depth of growth Microaerophilic Microaerophilic Aerophilic Microaerophilic
Biochemical [1,13,17]
Nitrate reductase Negative to weakly positive Negative to weakly positive Present Absent
Niacin production Negative to weakly positive Negative to weakly positive Present Absent
Drug susceptibility [3]
Pyrazinamide (PZA) Sensitive Sensitive Sensitive Resistant
Thiophene-2-carboxylic
acid hydrazide (TCH)
Sensitive Sensitive Resistant Sensitive
Molecular
Large sequence
polymorphisms
RD711 RD702 [4,5]
SNPs—see Table S1 [23]
Spoligotype analysis AFRI 2 & 3; absence of spacers
8–12 & 37–39
AFRI 1; absence of spacers
7–9 & 39
Absence of
spacer 34
Absence of spacers
39–43
[16]
IS6110 RFLP Average of 10 bands Average of 5 bands [17,18]
doi:10.1371/journal.pntd.0000744.t001
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Country n West African 1 (MAF1) West African 2 (MAF2) M. africanum
b Year Reference
Benin 152 93 (66%) 1982 [13]
Benin 194 55 (39%) 13 (9%) 2005–2006 2009
a [34]
Burkina Faso 102 17 (18%) 1979 [52]
Burkina Faso 80 25 (31%) 1982 [13]
Burkina Faso 378 (18%) 1992–1994 1996 [79]
Burkina Faso 120 0 2 (1.7%) 2007
a [80]
Cameroon (56%) 1971 [31]
Cameroon 455 40 (9%) 0 1997–1998 2003 [32]
The Gambia 359 0 138 (38%) 2002–2006 2009 [2]
Ghana 99 42 (42%) 1989 [81]
Ghana 64 13 (20%) 2003 2007 [82]
Ghana 1921 8.4% 21% 2001–2004 2008 [49]
Guinea Bissau 229 0 117 (51%) 1999
a [1]
Mali 203 66 (33%) 1973 1974 [11]
Mali 214 66 (31%) 1982 [13]
Mali 119 2 (1.7%) 33 (28%) 2006–2008 2009 [54]
Niger 178 81 (46%) 1982 [13]
Nigeria 55 human; 17
cattle
6 (11%) human;
1 (5.9%) cattle
0 2006 [60]
Senegal 69 7 (10%) 1994–1995 1999
a [83]
Sierra Leone 441 122 (28%) 1992–1993 1997 [84]
Sierra Leone 97 17 (18%) 2003–2004 2008 [85]
aEstimates based on interpretation of signature spoligotype patterns in this reference.
bAs defined by biochemical criteria.
doi:10.1371/journal.pntd.0000744.t002
Figure 3. M. africanum prevalence in Western African countries. Prevalence figures were derived from the most recently published studies
from Table 2 and unpublished data from Tunisia, Senegal, Cote d’Ivoire, Cameroon, and the Central African Republic extracted from the SITVIT2
proprietary database of Institut Pasteur de la Guadeloupe. If studies did not list the prevalence of MAF1 and/or MAF2, the estimates were based on
interpretation of the spoligotype patterns. Areas with MAF1 are shaded in brown and areas with MAF2 are shaded in green, with striped shading if
prevalence of MAF1 and MAF2 exceeds 5% each. Map courtesy of http://www.theodora.com/maps/, used with permission.
doi:10.1371/journal.pntd.0000744.g003
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the absence of caseation [64]. Using isolates from Ghana (where
MAF1 is more prevalent than MAF2), M. africanum was found to
be equally virulent as M. tuberculosis in guinea pigs, but avirulent in
rabbits [9]. Isolates from Central Africa (MAF1 or M. tuberculosis)
were found to be equally virulent in rabbits compared with M.
tuberculosis [65]. Tuberculin skin tests, using purified protein
derivative (PPD) derived from the respective organisms as well
as from Mycobacterium avium, showed cross-reaction between M.
tuberculosis and M. africanum PPD both in humans and in animals
[66,67].
In a recent study, BALB/c and C57BL/6 mice were infected
with different clinical MAF2 isolates by intravenous tail vein
infection and by intra-tracheal aerosol, and bacterial replication
in spleen and lungs was compared to infection with M.
tuberculosis H37Rv (K. Huygen, unpublished data). Significant
differences in growth were observed between MAF2 isolates:
some isolates displayed the same virulence as M. tuberculosis
reflected by increasing numbers of CFU in lungs, while other
MAF2 isolates showed an attenuated phenotype with little
colonization of the lungs. These findings suggest that phenotypic
differences exist within the lineage of MAF2 in mouse models,
which may in turn explain the variable results in guinea pigs and
rabbits.
Clinical and Epidemiological Differences between
M. africanum and M. tuberculosis
In The Gambia, where we identified M. africanum (exclusively
MAF2) in sputa of 38% of smear-positive TB patients, we
identified various clinical and epidemiological differences between
MAF2 and M. tuberculosis [68,69]. In a recent multivariable
analysis, we compared patients infected with MAF2 (n=289)
relative to the Euro-American lineage of M. tuberculosis (EAMTB,
n=403), which represent 90% of M. tuberculosis sensu stricto
isolates in The Gambia [70]. We found that TB patients infected
with MAF2 were more likely to be older, to be HIV infected, and
to be severely malnourished (Table 3). MAF2 patients were more
likely to have more than half the lung fields involved on chest X-
ray, despite a similar duration of cough. There was no difference
in the proportion of patients with a BCG scar between the two
organisms. MAF2 patients were less likely to produce IFNc in an
ESAT-6/CFP-10 ELISPOT assay (OR 0.32, 95% CI 0.18–0.59,
p,0.0001), although results of tuberculin skin testing were similar
[63]. Similarly, MAF2-exposed household contacts were less likely
to respond to ESAT-6 in an IFNc ELISPOT assay than were
those exposed to M. tuberculosis [63]. Transmission of MAF2 from
TB patients to their household contacts occurred at the same rate
as that of M. tuberculosis, as measured by the tuberculin skin test at
baseline and at 3 months, yet household contacts exposed to
MAF2 were less likely to develop TB disease in the next 2 years
than were contacts exposed to M. tuberculosis [71]. The mortality
on TB treatment in HIV-negative TB patients was similar between
the two organisms, around 3% [69]. The association with HIV
infection and the lower progression to disease in HIV-negative
patients suggest that MAF2 is somewhat attenuated compared to
M. tuberculosis. The older age of MAF2 patients may reflect the
lower rate of progression to disease. The lower rate of IFNc
responses against ESAT-6 by TB cases infected with MAF2 and
their exposed contacts may result from defective ESAT-6
secretion, consistent with preliminary results of ESAT-6 immu-
noblots of culture filtrates of MAF2 and M. tuberculosis. It is unclear
whether this ESAT-6 secretion defect results from the fact that the
Rv3879c gene in the RD1 region is non-functional in MAF2 [63].
In a Mycobacterium marinum model, Rv3879c was found to be
essential for ESAT-6 but not CFP-10 secretion [72]. However, an
M. bovis BCG recombinant strain with a deletion of Rv3878 to
Rv3881 efficiently secreted the ESAT-6 and CFP-10 antigens.
Similarly, a clinical M. tuberculosis isolate lacking Rv3878 and
Rv3879c was found to secrete both ESAT-6 and CFP-10 [73], and
an M. bovis null mutant of the Rv3879c homolog was not
attenuated for growth in guinea pigs [74]. More work is needed
to elucidate the molecular basis of the lower ESAT-6 response in
Table 3. Epidemiological, Clinical, and Immunological Differences of M. africanum Relative to M. tuberculosis.
Characteristic Country M. africanum
OR
(95% CI) p-Value Reference
West African 1 West African 2
Molecular clustering (IS6110 RFLP) Ghana Lower 0.38
(0.3–0.5)
,0.001 [49]
Progression to disease in first two
years after exposure
The Gambia Lower 3.1
(1.1–8.7)
0.036 [71]
Prevalence of HIV co-infection The Gambia Higher 2.13
(1.2–3.8)
0.010 [68] [86]
Ghana Same as MTB NS [49]
IFNc response to ESAT-6 The Gambia Lower 0.32
(0.18–0.59)
0.0001 [63,86]
Age The Gambia Older 2.0
(1.3–2.9)
0.001 [86]
Ghana Same as MTB NS [49]
Chest X-ray involvement The Gambia Worse 1.6
(1.1–2.1)
0.005 [86]
Ghana Less lower lobe disease in HIV-negative patients 0.34
(0.2–0.6)
,0.001 [49]
Underlined text indicates results from the study from Ghana, which combined the West African 1 and 2 data.
Italic text indicates results from the study from The Gambia, which only identified West African 2.
CI, confidence interval; ESAT-6, early secreted antigen- 6 kDa; IS6110 RFLP, insertion sequence 6110 restriction fragment length polymorphisms; MTB, M. tuberculosis.
doi:10.1371/journal.pntd.0000744.t003
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africanum.
Studying nearly 2,000 TB patients from Ghana, 29% of whom
were infected with M. africanum (MAF1 and MAF2 combined) as
opposed to M. tuberculosis, no differences in the rates of HIV co-
infection, nor chest X-ray severity, were seen between these
organisms [49]. HIV-negative M. tuberculosis patients were
significantly more likely to have exclusively lower zone disease
on chest X-ray. Chest X-rays did not differ between MAF1 and
MAF2. M. africanum patients were significantly less likely to have
recently transmitted disease (i.e., be part of a transmission cluster)
as opposed to reactivation disease. A lower clustering rate in M.
africanum compared to M. tuberculosis is consistent with the lower
progression to disease observed in The Gambia.
Similar to early findings in Dakar [6], we observed a longer time
to growth in culture of MAF2 relative to M. tuberculosis on primary
isolation from sputum, both in liquid and solid medium, adjusted
for the degree of smear positivity and extent of disease on chest X-
ray (p,0.0001, B. de Jong, unpublished data).
Unanswered Questions
The reason why M. africanum has not established itself outside of
the West Africa region remains enigmatic. Potential explanations
for the limited geographic spread of M. africanum despite massive
migrations of West Africans to the Americas at the time of the
slave trade include the possibility that diseased slaves did not
survive the crossing of the Atlantic, or that M. africanum did initially
establish itself in the New World, but was subsequently
outcompeted by M. tuberculosis, possibly due to its lower rate of
progression to disease relative to M. tuberculosis. Moreover, M.
africanum may not have established itself in the indigenous
American people and in their European colonizers if this organism
has a host preference for ethnically West African persons. Indeed,
a recent study described a host polymorphism found in Ghana that
is associated with protection against Euro-American M. tuberculosis,
yet not against M. africanum, and may thus have provided a
selective advantage for M. africanum in West African populations
[75]. Studies of innate immune responses in individuals of different
ethnic origins could test the hypothesis that M. africanum has
adapted to preferentially establishing infection in West African
hosts [5].
A West African animal reservoir of MAF2 that sustains a large
reservoir of latent infection in humans, and maintains MAF2 in
the human population despite a lower rate of progression, would
be in line with the phylogenetic relatedness of MAF2 and the
animal strains within the MTBC. A larger reservoir of latent
infection of MAF2 in The Gambia could in turn explain the
association with HIV infection seen in that country, yet not in
Ghana. However, a putative animal reservoir is more difficult to
invoke for MAF1 given that this lineage is phylogenetically more
distant from the classical animal-adapted sub-species of the MTBC
(Figure 2).
As DNA extraction from organisms causing latent infection is
impossible with the currently available technologies, we need new
tools to distinguish between latent infections with different sub-
species within the MTBC. We found that antigens from the TbD1
region, present in M. africanum but absent from M. tuberculosis,
failed to induce a T cell response that could be measured in an
IFNc ELISPOT [76]. Availability of the whole genome sequence
of a strain of MAF2 [77] will facilitate identification of other
potentially differential T cell and B cell epitopes. Establishing such
tools would allow us to compare the size of the reservoir of latent
infection with M. africanum relative to M. tuberculosis, and to answer
whether MAF2, with its lower rate of progression to disease,
protects against progression to disease of M. tuberculosis. Such a
protection could explain why MAF2, with its lower rate of
progression and shared host, has not been out-competed by M.
tuberculosis.
Understanding the genotypic differences underlying the pheno-
typic differences between MAF2 and M. tuberculosis can greatly
enhance our understanding of TB pathogenesis. To this end, the
completion of the MAF2 whole genome sequence will facilitate
experimental studies on the biological differences between MAF2
and M. tuberculosis, such as candidate genes that may underlie the
attenuated ESAT-6 response induced by MAF2. In addition, more
research should be dedicated to MAF1, as little is known on
putative phenotypic characteristics of this M. africanum lineage. To
successfully address all of these research questions, a comprehen-
sive and multidisciplinary ‘‘systems epidemiology’’ approach will
be necessary [78].
In conclusion, MAF 1 and MAF 2 are phylogenetically
‘‘ancient’’ sub-species within the MTBC that show phenotypic
Learning Points
N M. africanum is a sub-species of the M. tuberculosis
complex that consists of two distinct lineages, West
African 1 and 2
N Unambiguous identification of M. africanum requires
molecular methods
N M. africanum is found only in West Africa, where it causes
up to half of human TB
N M. africanum West African 2 has distinct phenotypes
compared to M. tuberculosis, such as a lower progression
to disease in exposed contacts, despite a similar rate of
transmission
N Infection with M. africanum responds to regular TB
treatment
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